Achromobacter xylosoxidans


Non-fermenting Gram-negative bacilli   
[cannot catabolize glucose and therefore are not able to ferment. Non-spore forming.]
>Acinetobacter baumannii
>Achromobacter xylosoxidans led
>Bordetella pertussis
>Burkholderia species:
     1] Burkholderia cepacia (also known as Pseudomonas cepacia) –  important
            pathogen of pulmonary infections in people with cystic fibrosis.
     2] Burkholderia pseudomallei (also known as Pseudomonas pseudomallei) 
>Elizabethkingia meningoseptica (Previously Chryseobacterium meningosepticum)
>Moraxella catarrhalis (formerly known as Branhamella catarrhalis)
>Pseudomonas aeruginosa
>Stenotrophomonas maltophilia (Initially classified as Pseudomonas maltophilia)

Achromobacter xylosoxidans

  • Gram-negative, aerobic, oxidase and catalase-positive, motile bacterium with peritrichous flagella, from the genus of Achromobacter which exist in water environment and was isolated from patients (pulmonary).
  • Achromobacter xylosoxidans can cause infections like bacteremia, especially for patients who suffer from cystic fibrosis.
  • The complete genome of Achromobacter xylosoxidans is sequenced.

top of page


Important considerations:  The choice of an agent should be based on local antimicrobial sensitivities, site of infection, cost, and comorbid conditions.   Generally, the most common agents/regimens are listed first. Listed dosages may need to be adjusted for renal dysfunction.  

Achromobacter xylosoxidans: Usually resistant to multiple antibiotics which complicates therapy.

  1. Cefepime 1-2 grams IV every 8-12 hours
  2. Bactrim Mild-moderate infection:  8 to 10 mg/kg/day (based on trimethoprim component)  IV divided in 2-4 doses.    Severe infection: 15 to 20 mg/kg/day (based on trimethoprim component)  IV, given in equally divided doses every 6 to 8 hours.
  3. Imipenem 500mg IV every 6 hours [Range: 250-1000 mg q6-8h]
  4. Meropenem 0.5 – 1 gram IV q8h


The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer